Cora Capital Advisors’s AstraZeneca AZN Stock Holding History

Cora Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,185	Closed	-$402K	–	137
2025 Q4	$402K	Buy	2,185 +197	+10%	+$34.6K	0.16%	72
2025 Q3	$305K	Buy	1,988 +6	+0.3%	+$908	0.13%	85
2025 Q2	$277K	Sell	1,982 -122	-6%	-$17.1K	0.12%	85
2025 Q1	$309K	Buy	2,104 +6	+0.3%	+$868	0.15%	75
2024 Q4	$275K	Buy	2,098 +6	+0.3%	+$840	0.13%	81
2024 Q3	$326K	Hold	2,092	–	–	0.16%	71
2024 Q2	$326K	Sell	2,092 -1	-0%	-$150	0.17%	67
2024 Q1	$284K	Hold	2,093	–	–	0.15%	73
2023 Q4	$282K	Sell	2,093 -28	-1%	-$3.64K	0.17%	75
2023 Q3	$287K	Sell	2,121 -3	-0.1%	-$410	0.19%	71
2023 Q2	$304K	Sell	2,124 -40	-2%	-$5.88K	0.2%	69
2023 Q1	$300K	Buy	2,164 +11	+0.5%	+$1.48K	0.22%	62
2022 Q4	$292K	Buy	+2,153	New	+$270K	0.2%	58

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Cora Capital Advisors's AZN Position: Q1 2026 in Review

Cora Capital Advisors sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 2,185 shares — an estimated $402K sold.

Cora Capital Advisors first reported a position in AZN in Q4 2022 and held it in 13 quarters. The position peaked at $402K in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Cora Capital Advisors reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Cora Capital Advisors sold 2,185 AstraZeneca shares in Q1 2026, an estimated $402K.
Cora Capital Advisors first reported a position in AstraZeneca in Q4 2022 and held it in 13 quarters.
Cora Capital Advisors's AstraZeneca position peaked at $402K in Q4 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Cora Capital Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.